Follow us on Twitter
twitter icon@FreshPatents


Dextran patents

      

This page is updated frequently with new Dextran-related patent applications.




 Method for the production of dextran patent thumbnailMethod for the production of dextran
Method for the production of dextran comprising the following steps: prepare a culture medium containing the appropriated mixture and balance of ingredients, mainly after accurate selection of nature and concentration of carbon and nitrogen sources, with a specific initial ph, inoculate the culture medium with an appropriated quantity of bacteria strain (to standardize the production and avoid as much as possible the variability of the system); carry out the fermentation for a given time and at a given temperature; precipitate the dextran to separate the product from the culture medium; the bacteria strain is a strain of weissella cibaria.. .
Bio-e.r.g. S.r.l.


 Process for producing and purifying factor viii and its derivatives patent thumbnailProcess for producing and purifying factor viii and its derivatives
Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.


 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran patent thumbnailCompositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
The subject invention relates to the compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran with technetium-99m and for stabilizing the dtpa-dextran cold kit. The composition contains stannous chloride ions to reduce 99mtc-pertechnetate, ascorbic acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and glycine to transchelate technetium-99m under highly acidic conditions to facilitate radiolabeling dtpa-dextran with high radiochemical purity.
Navidea Biopharmaceuticals, Inc.


 Medical fluid, a  treatment and use of the fluid patent thumbnailMedical fluid, a treatment and use of the fluid
A medical fluid for a harvested organ, tissue or part thereof, for evaluation and/or preservation. The fluid includes cocaine or a stimulating analogue thereof; noradrenaline; and/or adrenaline.
Vivoline Medical Ab


 Anti-microbial agents and uses therefor patent thumbnailAnti-microbial agents and uses therefor
The invention relates generally to methods and materials (for example animal feeds) which use dextranases for treating or controlling campylobacter infection or colonisation, or disrupting campylobacter biofilms. The invention has utility inter alia in eradicating or reducing the prevalence of campylobacter in a population of animals, such as poultry..
Ucl Business Plc


 Method and kit for detection of microorganism patent thumbnailMethod and kit for detection of microorganism
3) a primer or primers for amplifying a target region of the dna or rna of the microorganism to be detected by a nucleic acid amplification method. The agent for suppressing a nucleic acid amplification inhibitory substance is one or more selected from albumin, dextran, t4 gene 32 protein, acetamide, betaine, dimethyl sulfoxide, formamide, glycerol, polyethylene glycol, soybean trypsin inhibitor, α2-macroglobulin, tetramethylammonium chloride, lysozyme, phosphorylase and lactate dehydrogenase..

 Construction of new variants of dextransucrase dsr-s by genetic engineering patent thumbnailConstruction of new variants of dextransucrase dsr-s by genetic engineering
The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the α-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences and host cells transformed by sequences encoding truncated or mutated dextransucrases.
Institut National Des Sciences Appliquees De Toulouse


 Bismuth-iron oxide contrast agents patent thumbnailBismuth-iron oxide contrast agents
Nanoparticles for use as a contrast agent, and methods for making and using the nanoparticles, are described, wherein each nanoparticle comprises a core comprising bismuth and iron oxide, and an outer coating (e.g., dextran) surrounding the core. The bismuth-iron oxide nanoparticles can be used in pre-clinical and clinical settings for both computed tomography (ct) and magnetic resonance (mr) imaging..
The Trustees Of The University Of Pennsylvania


 Trace elements patent thumbnailTrace elements
A trace element solution comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronization preparation. The synchronization preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation.
Warburton Technology Limited


 Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity patent thumbnailInjectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity
Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.. .
Cti Biopharma Corp.


Gamma sterilized dextran solutions and methods of use

Provided herein are kit for providing a gamma sterilized aqueous dextran solution that increase the efficiency of blood separation by allowing the dextran solution to be sterilized by exposure to gamma radiation while maintaining sufficient molecular weight to act as a red blood cell aggregate. Also provided are methods of use..
General Electric Company

Zwitterionic polysaccharide polymers having antifouling, antimicrobial and optical transparency properties

The present invention is directed to facile method of zwitteration of polysaccharides or other polymers with carboxybetaine (cb) or another zwitterionic betaine. Zwitterionic cb functional groups were seamlessly integrated onto dextran backbone via a one pot reaction.
The University Of Akron

Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof

Disclosed is a mucoadhesive nanoparticle delivery system for delivering an immunosuppressant, such as cyclosporine a, to a mucosal site for treatment of a disease or condition involving inflammation or excess immune activity. The system comprises nanoparticles formed from a plurality of linear amphiphilic block copolymers, each having a hydrophobic block comprising polylactide (pla) and a hydrophilic block comprising dextran.
University Of Waterloo

Improvements relating to encapsulated benefit agents

A process for the preparation of a particle, wherein the particle comprises: (a) a core comprising a hydrophobic benefit agent; (b) an outer crosslinked shell, which comprises a crosslinked, hydrophobically modified polyvinyl alcohol, which comprises a crosslinking agent comprising a first dextran aldehyde having a molecular weight of from 2,000 to 2,000,000 da; and (c) an inner polyamide shell, wherein the shell comprises a polyamide, and wherein the polyamide comprises an aromatic group; wherein the outer crosslinked shell is formed prior to the formation of the inner polyamide shell.. .
Conopco, Inc., D/b/a Unilever

Low swell tissue adhesive and sealant formulations

A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized dextran containing pendant aldehyde groups with a multi-arm polyethylene glycol amine is described. The hydrogel exhibits little to no swell upon exposure to physiological conditions.

Magnetic separation of lipoproteins using dextran sulfate

The invention provides apparatus and methods of preparation of lipoproteins from a biological sample, including hdl, ldl, lp(a), idl, and vldl, for diagnostic purposes utilizing differential charged-particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged-particle mobility, which lipoproteins are prepared by methods of the invention.

New use of dextran sulfate

A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 da.. .
Tx Medic Ab

Materials and methods for preventing and treating microbe-mediated epithelial disorders

The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as l-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis.
The University Of Chicago

Enzymatically polymerized gelling dextrans

Compositions are disclosed herein comprising dextran that comprises (i) 87-93 wt % glucose linked at positions 1 and 6; (ii) 0.1-1.2 wt % glucose linked at positions 1 and 3; (iii) 0.1-0.7 wt % glucose linked at positions 1 and 4; (iv) 7.7-8.6 wt % glucose linked at positions 1, 3 and 6; and (v) about 0.4-1.7 wt % glucose linked at (a) positions 1, 2 and 6, or (b) positions 1, 4 and 6. Aqueous forms of this composition have enhanced viscosity profiles.
E I Du Pont De Nemours And Company

Dextran sulfate for use in mobilization of cells

dextran sulfate in a range of 3500 and 9500 da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration..
Tx Medic Ab

Trehalose and dextran-containing solution for transplanting mammalian cells

The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran).
Otsuka Pharmaceutical Factory, Inc.

Co-crosslinked phosphated native and/or functionalized polysaccharide-based hydogel

Phosphorylated hydrogels obtained by co-cross-linking hyaluronic acid with dextran, a process for preparing same, and a use of the hydrogel for the encapsulation and extended release of active principles as well as cells for use in regenerative human and veterinary medicine.. .
Ayawane

Injectable nano-network gels for diabetes treatment

A system for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3d scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated.
The Children's Medical Center Corporation

Polypeptides having dextranase activity and polynucleotides encoding same

The present invention relates to isolated polypeptides having dextranaseactivity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Method of causing delayed hemostasis

A method of causing delayed hemostasis. A hemostatic product is formed by applying a hemostatic agent to a dextran support.
St. Teresa Medical Inc.

Bioresorbable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release

Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent..
Royer Biomedical, Inc.

Medium supplements for improved process performance

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate..
Biogen Ma Inc.

Biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate, and preparation method therefor

The present invention relates to: biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate; a preparation method therefor; and a method for treating cancer using the same. The microbeads of the present invention is prepared from a biocompatible and biodegradable polymer so as to be safe to the human body, and can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrition to a liver tumor and continuously releasing an anticancer drug adsorbed on surfaces of the beads.
Utah-inha Dds & Advanced Therapeutics Research Center

Construction of new variants of dextransucrase dsr-s by genetic engineering

The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the α-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences and host cells transformed by sequences encoding truncated or mutated dextransucrases.
Institut National Des Sciences Appliquees De Toulouse

Glycan profiling utilizing capillary electrophoresis

A method for glycan profiling by capillary electrophoresis (ce), and a ce system for glycan analysis (n-glycan). The ce system uses integrated dual optical fibers for both radiation excitation and emission detection.
Bioptic, Inc.

Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation

The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.. .
Pharmacosmos A/s

Freeze-dried excipient and preparation method thereof

A freeze-dried excipient and a preparation method thereof. The freeze-dried excipient only comprises an active ingredient and a binder, and does not comprise a support agent.

Gamma stabilized dextran solutions and methods of use

Provided herein are gamma stable dextran solutions and kits that increase the efficiency of blood separation by allowing the dextran solution to be sterilized by exposure to gamma radiation and maintain sufficient molecular weight to act as a red blood cell aggregant. Further provided are methods of use..
General Electric Company

Encapsulated benefit agents

The invention provides improved deposition and reduced leakage benefits from a particle comprising: (a) a core comprising a benefit agent; (b) a shell, wherein the shell comprises a crosslinked, hydrophobically modified polyvinyl alcohol, which comprises a crosslinking agent comprising i) a first dextran aldehyde having a molecular weight of from 2,000 to 50,000 da; and ii) a second dextran aldehyde having a molecular weight of from greater than 50,000 to 2,000,000 da.. .

Water-based ink for ink-jet recording, water-based ink set for ink-jet recording, and treatment agent

A water-based ink for ink-jet recording includes a self-dispersible pigment which is modified with phosphate group, at least one of dextran and a derivative thereof, and water.. .
Brother Kogyo Kabushiki Kaisha

Absorbable compositions and methods for their use in hemostasis

The present invention is direct to a body-absorbable, mechanically hemostatic composition comprising a solid poloxamer having an average molecular weight of about 7,000 g/mol to about 15,000 g/mol, a high molecular weight dextran, optionally a fatty acid salt, and water, and a method for mechanically controlling the bleeding of bone comprising applying an effective amount of the composition to the affected area.. .
Pioneer Surgical Technology, Inc.

Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

A composition in the form of an injectable aqueous solution, the ph of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pi of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a ph of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin..
Adocia

Dextran-peptide hybrid for efficient gene delivery

One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells.
The University Of Akron

Colonic drug delivery formulation

A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a ph threshold at about ph 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.. .
University College London

Traditional chinese medicine composition for pigment repair

The invention provides a composition for use in traditional chinese medicine to repair the pigment, wherein said composition comprises the following parts by weight of the composition ratio of raw material: 5-10 parts water, rhodiola extract 2-6 copies, snow lotus root extract 3-5 parts, 1-5 parts egeria motherwort extract, vitamin-c2-3 copies, copies of oat amino acids 2-5, 2-3 parts of dextran, 1-2 parts of emu oil, astragalus extract 2-3 parts, 4-5 parts of ginseng root extract, angelica extract 2-3 parts. This composition helps dilute pigment and redness, thickening of the skin to make the skin more resistant to ease fragile, net flashed white luster..
Shang Chen Mei Bang (beijing) Biotechnology Co., Ltd.

Traditional chinese medicine composition for dispelling wringles and black eye and its preparation method

The invention provides a composition and method for preparing medicine for eye bags and dark circles fade, wherein said composition comprises the following parts by weight ratio of raw material composition: 10-15 parts water, ganoderma lucidum extract 2-3 copies, black ganoderma extract 3-4, 5-6 parts wheat germ oil, sucrose laurate 2-3 parts, 3-5 parts chamomile extract, 3-5 parts of milk protein, yeast ferment filtrate 3-5 copies, dextran 2-3 copies, copies tremella 2-4, 2-3 parts angelica root extract, astragalus extract 2-3 parts. The above described method for preparing a composition according to the present invention, without any side effects, can be soft smooth skin around the eyes, remove free radicals, enhance the resilience of the skin, thereby improving eye skin color, to get rid of dark circles effect..
Shang Chen Mei Bang (beijing) Biotechnology Co., Ltd.

Evaluation and preservation solution

An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/l, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/l weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.. .
Xvivo Perfusion Ab

Compositions comprising short-acting benzodiazepines

A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran.. .
Paion Uk Limited

Multi-layered anti-adhesion device

Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix.

Waterborne topical compositions for the delivery of azelaic acid for treatment of skin conditions such as acne vulgaris, rosacea, seborrheic dermatitis

A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. One composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound.
Epikinetics Pharma, Llc



Dextran topics:
  • Recombinant
  • Recombinant Protein
  • Ophthalmic
  • Ascorbic Acid
  • Polysaccharides
  • Ethylene Glycol
  • Hydroquinone
  • Cultured Cells
  • Culture Media
  • Epithelial
  • Epithelial Cell
  • Eukaryotic
  • Fibroblast
  • Cell Culture Media
  • Magnetic Field


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Dextran for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dextran with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.0394

    file did exist - 2198

    2 - 1 - 51